As opioid crises evolve worldwide, clinicians have begun to notice new and unexpected forms of drug misuse. One emerging pattern, especially visible in Egypt over the past decade, is the injection of anticholinergic ophthalmic (eye drop) solutions alongside heroin. Though seemingly niche, this behavior may carry serious neurological consequences. A new comparative study from Ain Shams University offers the first structured scientific look at how this combination affects cognitive function - and the findings raise important concerns.
The study analyzed 60 adults split into three groups: 20 healthy controls, 20 intravenous heroin users, and 20 individuals who not only injected heroin but also misused anticholinergic eye drops intravenously. Anticholinergics, which block acetylcholine signaling, are known to impair memory and attention when taken systemically. Combined with heroin's own cognitive effects, researchers speculated this dual misuse might produce unique or amplified deficits.
To test this, participants underwent a wide battery of neurocognitive assessments. These included the Trail Making Test (for attention and processing speed), the Benton Visual Retention Test (for visual memory and reconstruction), the Wechsler Memory Scale (for auditory, visual, immediate, and working memory), and the Wisconsin Card Sorting Test (for abstract reasoning and cognitive flexibility). The groups were matched for age and sex, and addiction severity was measured using the Addiction Severity Index.
The results were striking: dual users - those injecting both heroin and eye drops - performed significantly worse on attention and processing speed compared to heroin-only users. Specifically, 75% of the dual-use group showed impairment on Trail Making Test A, versus 45% of heroin-only users. This difference was large enough to be statistically significant.
Attention and processing speed are foundational cognitive functions that support everything from decision-making to impulse control. Deterioration in these areas increases vulnerability to risky behavior, reduces treatment engagement, and may contribute to broader cognitive decline. In real-world terms: slower processing means slower judgment, poorer response times, and impaired ability to regulate or navigate daily life.
Interestingly, for other tests - visual memory, working memory, and executive function - the dual-use group did not show statistically significant differences compared to the heroin-only group. All heroin users, regardless of subtype, scored significantly lower than healthy controls, showing the well-known cognitive toll of chronic opioid use. But the group using anticholinergic drops showed one specific amplified vulnerability: their attentional system appeared disproportionately impaired.
This pattern aligns with known pharmacology. Anticholinergic substances inhibit acetylcholine, a neurotransmitter heavily involved in attention, arousal, working memory, and cortical processing. High systemic anticholinergic burden - whether from medications or substance misuse - is consistently associated with slower cognitive processing and elevated dementia risk in long-term exposures. Injecting ophthalmic anticholinergics (never intended for systemic delivery) may create toxic concentration spikes, disproportionately affecting cholinergic circuits in the cortex.
Heroin, meanwhile, depresses central nervous system activity and alters reward pathways, leading to deficits in executive function, memory, and emotional regulation. When combined, the depressant effect of heroin and the cognitive-disorganizing effect of anticholinergics may create a "dual-hit" pattern: different mechanisms converging on overlapping brain networks.
The study also found negative correlations between cognitive performance and both age and addiction severity. In other words, older participants and those with more severe addiction histories showed deeper impairments. This is consistent with international research showing that chronic opioid exposure interacts with aging to accelerate cognitive decline.
Although the sample size was modest, the findings offer an important early window into an underrecognized risk. They highlight how polysubstance misuse involving legally available medications - or medical products like eye drops - can create new pathways of harm not yet captured in traditional drug monitoring systems.
Culturally, this phenomenon reflects a larger global pattern: as drug regulation tightens and street markets fluctuate, people who inject drugs may seek alternative substances that are inexpensive, legal, or easily available. Anticholinergic eye drops are often sold over the counter, making them accessible to individuals unable to afford or acquire additional illicit substances to enhance the effects of heroin. But the neurological cost of this strategy may be far greater than users realize.
The authors call for increased awareness among clinicians, public health workers, and harm reduction programs, particularly in regions where eye drop misuse is growing. Routine cognitive screening in treatment settings may help identify individuals at risk for attentional deficits, allowing for targeted interventions. The findings also underscore the need to regulate or monitor substances with psychoactive potential, especially when diverted from medical use.
Ultimately, this study highlights a simple but crucial truth: not all forms of substance combination are equal - some strike directly at core cognitive systems that are essential to recovery and long-term stability.
From the perspective of Seven Reflections' Dimensional Systems Architecture (DSA), heroin use already destabilizes the cognitive field by depressing core integrative functions and weakening field coherence. Introducing anticholinergic substances creates an additional disruption, targeting the attentional axis - the system responsible for orienting, selective focus, and temporal processing. In DSA terms, this creates a "field interference pattern" where dual neurochemical pathways collide, overloading the system's regulatory bandwidth.
Processing speed and attention act as stabilizing layers within the cognitive field. When these collapse, the entire system becomes less predictive, less adaptive, and more fragmented. The study's finding that anticholinergic misuse specifically amplifies attentional impairment aligns with DSA's expectation: when a stabilizing axis is compromised, the rest of the cognitive structure becomes more vulnerable, even if some functions appear unchanged. This provides a field-level explanation for why dual use produces disproportionate cognitive harm.
